Fastenal Company Announces Cash Dividend

Fastenal Company Announces Cash Dividend

WINONA, Minn.–(BUSINESS WIRE)–
Fastenal Company (Nasdaq:FAST) (collectively referred to as ‘Fastenal’ or by terms such as ‘we’, ‘our’, or ‘us’) reported its board of directors declared a dividend of $0.44 per share to be paid in cash on May 23, 2025 to shareholders of record at the close of business on April 25, 2025. Except for share and per share information, dollar amounts are stated in millions.

We began paying annual dividends in 1991, semi-annual dividends in 2003, and then expanded to quarterly dividends in 2011. In addition to these regular dividend payments, we have previously paid special one-time dividends in December 2008, December 2012, December 2020, and December 2023. Our board of directors currently intends to continue paying quarterly dividends, though all future determination as to payment of dividends will depend upon the financial condition and results of operations of Fastenal and such other factors as are deemed relevant by the board of directors at that time.

In 2025, 2024, and 2023, we paid (or declared) dividends as follows:

Year

 

First

Quarter

 

Second

Quarter

 

Third

Quarter

 

Fourth

Quarter

 

Sub-Total

(Regular)

Fourth Quarter

(Special)

 

Total

2025

 

$

0.43

 

$

0.44

 

 

 

 

 

 

 

 

 

2024

 

$

0.39

 

$

0.39

 

$

0.39

 

$

0.39

 

$

1.56

$

0.00

 

$

1.56

2023

 

$

0.35

 

$

0.35

 

$

0.35

 

$

0.35

 

$

1.40

$

0.38

 

$

1.78

Dividend and common stock purchase activity during the last ten years:

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Value

Total

Average Per

 

 

Total

Dividends per Share

of Common

Number

Share Price of

 

Dividend

Dividends

Regular

 

Special

 

Total

 

Stock

of Shares

Common Stock

Year

Payments

Paid

Dividend

 

Dividend

 

Dividend

 

Purchased

Purchased

Purchased

2025

Two (1)

 

$

499.0

 

 

$

0.87

 

 

$

 

$

0.87

 

 

$

 

 

 

 

$

 

2024

Four

 

$

893.3

 

 

$

1.56

 

 

$

 

$

1.56

 

 

$

 

 

 

 

$

 

2023

Five (2)

 

$

1,016.8

 

 

$

1.40

 

 

$

0.38

 

$

1.78

 

 

$

 

 

 

 

$

 

2022

Four

 

$

711.3

 

 

$

1.24

 

 

$

 

$

1.24

 

 

$

237.8

 

 

5,000,000

 

 

$

47.58

 

2021

Four

 

$

643.7

 

 

$

1.12

 

 

$

 

$

1.12

 

 

$

 

 

 

 

$

 

2020

Five (2)

 

$

803.4

 

 

$

1.00

 

 

$

0.40

 

$

1.40

 

 

$

52.0

 

 

1,600,000

 

 

$

32.54

 

2019

Four

 

$

498.6

 

 

$

0.87

 

 

$

 

$

0.87

 

 

$

 

 

 

 

$

 

2018

Four

 

$

441.9

 

 

$

0.77

 

 

$

 

$

0.77

 

 

$

103.0

 

 

4,000,000

 

 

$

25.75

 

2017

Four

 

$

369.1

 

 

$

0.64

 

 

$

 

$

0.64

 

 

$

82.6

 

 

3,800,000

 

 

$

21.72

 

2016

Four

 

$

346.6

 

 

$

0.60

 

 

$

 

$

0.60

 

 

$

59.5

 

 

3,200,000

 

 

$

18.58

 

Ten Year Total

 

 

$

6,223.7

 

 

$

10.07

 

 

$

0.78

 

$

10.85

 

 

$

534.9

 

 

17,600,000

 

 

$

30.39

 

(1)

The Total Dividends Paid amount includes the estimated impact from this announcement. The estimate is calculated using the 573.6 million shares outstanding at March 31, 2025.

(2)

There was a supplemental dividend paid in December 2020 and December 2023.

In the first quarter of 2025, we did not repurchase any of our common stock.

We have authority to purchase up to 6,200,000 additional shares of our common stock under the July 12, 2022 authorization. This authorization does not have an expiration date.

All share and per share information reflects the two-for-one stock split in 2019.

About Fastenal

With more than 3,500 in-market locations spanning 25 countries, Fastenal supplies a broad offering of fasteners, safety products, metal cutting products, and other industrial supplies to customers engaged in manufacturing, construction, warehousing, wholesale, and state and local government. By investing in local experts and inventory, customer-facing technology, wide-ranging services, and best-in-class sourcing and logistics, we offer a unique combination of capabilities to help our customers reduce cost, risk, and scalability constraints in their global supply chains. This “high-touch, high-tech” approach is reflected in our tagline, Where Industry Meets Innovation™.

Additional information regarding Fastenal is available on our website at www.fastenal.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are not historical in nature and that are intended to be, and are hereby identified as, “forward looking statements” as defined in the Private Securities Litigation Reform Act of 1995, including a statement regarding expectations as to payment of a quarterly cash dividend in the foreseeable future. Any future determination as to payment of dividends will depend upon the financial condition and results of operations of Fastenal and such other factors as are deemed relevant by the board of directors. For example, a change in business needs including working capital and funding for acquisitions, or a change in income tax law relating to dividends or stock repurchases, could cause us to decide not to pay a dividend in the future or not to repurchase common stock pursuant to the existing share repurchase authorization. A discussion of other risks and uncertainties is included in our filings with the Securities and Exchange Commission, including our most recent annual report and subsequent quarterly reports.

FAST-D

Taylor Ranta Oborski

Accounting Manager

507.313.7959

KEYWORDS: United States North America Minnesota

INDUSTRY KEYWORDS: Machine Tools, Metalworking & Metallurgy Other Construction & Property Manufacturing Construction & Property Other Manufacturing Machinery

MEDIA:

Logo
Logo

Curbline Properties’ First Quarter Earnings Conference Call to Be Held on Thursday, April 24, 2025, at 8:00AM

Curbline Properties’ First Quarter Earnings Conference Call to Be Held on Thursday, April 24, 2025, at 8:00AM

NEW YORK–(BUSINESS WIRE)–
Curbline Properties Corp. (NYSE: CURB), an owner of convenience shopping centers positioned on the curbline of well-trafficked intersections and major vehicular corridors in suburban, high household income communities, announced today that financial and operational results for the quarter ended March 31, 2025 will be released prior to the market open on April 24, 2025. The Company will host its quarterly earnings conference call and audio webcast on April 24, 2025 at 8:00am Eastern Time.

All interested parties can access the earnings call by dialing +1(800) 715-9871 (U.S.) or +1(646) 307-1963 (international) using passcode 6823859. The live webcast can also be accessed by clicking the following link: 1Q25 Curbline Properties Earnings Conference Call

If you are unable to participate during the live call, a replay will be available on Curbline Properties’ website for future review. You may also access the telephone replay by dialing +1(800) 770-2030 (U.S.) or +1(609) 800-9909 (international) using passcode 6823859 through May 1, 2025.

About Curbline Properties

Curbline Properties is an owner and manager of convenience shopping centers positioned on the curbline of well-trafficked intersections and major vehicular corridors in suburban, high household income communities. The Company is publicly traded under the ticker symbol “CURB” on the NYSE and plans to elect to be treated as a REIT for U.S. federal income tax purposes. Additional information about Curbline is available at www.curbline.com. To be included in the Company’s e-mail distributions for press releases and other investor news, please click here.

Conor Fennerty,

EVP and Chief Financial Officer

(216) 755-6200

curbline.com

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Jewelry Food/Beverage Fashion Home Goods Retail Convenience Store REIT Luxury Discount/Variety Department Stores Commercial Building & Real Estate Construction & Property Office Products Restaurant/Bar Other Retail Wine & Spirits Tobacco Supermarket

MEDIA:

Logo
Logo

Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025

EL MONTE, Calif.–(BUSINESS WIRE)–
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2025 financial results before the market opens on Friday, May 2, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.

The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.

About Fulgent

Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company.

Investor Relations Contact:

The Blueshirt Group

Melanie Solomon, [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Oncology Health Health Technology Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Floor & Decor Holdings, Inc. Announces First Quarter Fiscal 2025 Earnings Conference Call

Floor & Decor Holdings, Inc. Announces First Quarter Fiscal 2025 Earnings Conference Call

ATLANTA–(BUSINESS WIRE)–
Floor & Decor Holdings, Inc. (NYSE: FND) today announced that its financial results for the first quarter of fiscal 2025 will be released after market close on Thursday, May 1, 2025. The company will host a conference call at 5:00 p.m. Eastern Time to discuss the financial results. A live audio webcast of the conference call, together with related materials, will be available online at ir.flooranddecor.com.

A recorded replay of the conference call will be available approximately three hours after the conclusion of the call and can be accessed both online at ir.flooranddecor.com and by dialing 844-512-2921 (international callers please dial 412-317-6671). The pin number to access the telephone replay is 13752521. The replay will be available until May 8, 2025.

About Floor & Decor Holdings, Inc.

Floor & Decor is a multi-channel specialty retailer and commercial flooring distributor operating 251 warehouse-format stores and five design studios across 38 states as of December 26, 2024. The Company offers a broad assortment of in-stock hard-surface flooring, including tile, wood, laminate, vinyl, and natural stone along with decorative accessories and wall tile, installation materials, and adjacent categories at everyday low prices. The Company was founded in 2000 and is headquartered in Atlanta, Georgia.

Investor Contacts:

Wayne Hood

Senior Vice President of Investor Relations

678-505-4415

[email protected]

or

Matt McConnell

Senior Manager of Investor Relations

770-257-1374

[email protected]

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Other Manufacturing Commercial Building & Real Estate Construction & Property Manufacturing Home Goods Building Systems Retail Other Construction & Property Residential Building & Real Estate

MEDIA:

Logo
Logo

Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025

Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025

PALO ALTO, Calif.–(BUSINESS WIRE)–
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Source: Guardant Health, Inc.

Investor Contact:

Zarak Khurshid

[email protected]

Media Contact:

Melissa Marasco

[email protected]

+1 650-647-3711

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Software Biotechnology Oncology Health Artificial Intelligence Data Management Health Technology Technology

MEDIA:

Logo
Logo

Twilio to Announce First Quarter 2025 Results on May 1, 2025

Twilio to Announce First Quarter 2025 Results on May 1, 2025

SAN FRANCISCO–(BUSINESS WIRE)–
Twilio Inc. (NYSE: TWLO), the customer engagement platform that drives real-time, personalized experiences for today’s leading brands, today announced that its first quarter 2025 results will be released on Thursday, May 1, 2025, after market close. Twilio will host a conference call at 2:00 p.m. (PT) / 5:00 p.m. (ET) on Thursday, May 1, 2025 to discuss its results with the investment community. Investors and analysts can register for the webcast at https://edge.media-server.com/mmc/p/qgo3e62v, and the live webcast and replay will also be available on the Twilio Investor Relations website at https://investors.twilio.com. The replay will be available until 11:59 p.m. (ET) on May 1, 2026.

Twilio uses its investor relations website (https://investors.twilio.com) and the X (formerly Twitter) account of the company (@twilio) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Twilio

Today’s leading companies trust Twilio’s Customer Engagement Platform (CEP) to build direct, personalized relationships with their customers everywhere in the world. Twilio enables companies to use communications and data to add intelligence and security to every step of the customer journey, from sales to marketing to growth, customer service and many more engagement use cases in a flexible, programmatic way. Across 180 countries and territories, millions of developers and hundreds of thousands of businesses use Twilio to create magical experiences for their customers. For more information about Twilio (NYSE: TWLO), visit: www.twilio.com.

Source: Twilio Inc.

Investor Contact:

Bryan Vaniman

[email protected]

or

Media Contact:

Caitlin Epstein

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Professional Services Data Management Technology Other Technology Software Finance Banking

MEDIA:

Logo
Logo

Procore Announces Timing of First Quarter Fiscal Year 2025 Earnings Call

Procore Announces Timing of First Quarter Fiscal Year 2025 Earnings Call

CARPINTERIA, Calif.–(BUSINESS WIRE)–Procore Technologies, Inc. (NYSE: PCOR), the leading global provider of construction management software, today announced that it will report its first quarter fiscal year 2025 financial results after the U.S. financial markets close on Thursday, May 1, 2025.

In conjunction with this announcement, Procore will host a conference call on Thursday, May 1, 2025 at 2:00 p.m. Pacific Time to discuss Procore’s financial results and financial guidance. To access this call, dial +1 833 470 1428 (domestic) or +1 404 975 4839 (international). The conference ID number is 007334. A live webcast of this conference call will be available on the Investor Relations page of Procore’s website, http://investors.procore.com, and a replay will be archived on the website as well. To access the live event please register here.

About Procore

Procore Technologies, Inc. (NYSE: PCOR) is a leading technology partner for every stage of construction. Built for the industry, Procore’s unified technology platform drives efficiency and mitigates risk through AI & data-driven insights and decision making. Over three million projects have run on Procore across 150+ countries. For more information, visit www.procore.com.

PROCORE-IR

Category: Earnings

Media Contact

[email protected]

Investor Contact

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Other Construction & Property Data Management Technology Construction & Property Software

MEDIA:

Logo
Logo

PROCEPT BioRobotics® Announces Investor Event at 2025 AUA Annual Meeting at the Aria Resort in Las Vegas

SAN JOSE, Calif., April 10, 2025 (GLOBE NEWSWIRE) — PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company, whose mission is to revolutionize BPH treatment globally, announced today it will host an in-person investor event on Friday, April 25, 2025, at the Aria Resort in Las Vegas at the American Urological Association Annual Meeting from 8:00am to 9:30am Pacific Time. Guests are encouraged to register in advance by clicking HERE. Registration is recommended to secure your spot.

Members of PROCEPT BioRobotics’ management team presenting include:

  • Reza Zadno – Chief Executive Officer
  • Kevin Waters – Chief Financial Officer
  • Sham Shiblaq – Chief Commercial Officer
  • Barry Templin – Chief Technology Officer

Clinical perspectives will also be provided by the following physicians:

  • Dr. Inderbir Gill – Founding Executive Director for USC Urology, Chairman of Urological Cancer Surgery at Keck School of Medicine of USC
  • Dr. Brian Helfand – Division Chief of Urology, Endeavor Health, Associate Chief Scientific Officer at Endeavor Health, Clinical Professor at University of Chicago, Ronald Chez Family and Richard Melman Family Endowed Chairman
  • Dr. Gerald Park – Partner, Kansas City Urology Care

A live webcast of the event, as well as an archived recording, will be available on the “Investors” section of the Company’s website at https://ir.procept-biorobotics.com/. The webcast will be archived and available for replay for at least 90 days after the event.

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics’ mission is to revolutionize BPH treatment globally in partnership with urologists by delivering best-in-class robotic solutions that positively impact patients and drive value. PROCEPT BioRobotics manufactures the AQUABEAM® and HYDROS™ Robotic Systems. The HYDROS Robotic System is the only AI-Powered, robotic technology that delivers Aquablation therapy. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe, and durable outcomes for males suffering from lower urinary tract symptoms or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The Company has developed a significant and growing body of clinical evidence with over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.

Important Safety Information

All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/

Investor Contact:

Matt Bacso
VP, Investor Relations and Business Operations
[email protected]



AppFolio, Inc. Announces Date of First Quarter 2025 Financial Results Conference Call

SANTA BARBARA, Calif., April 10, 2025 (GLOBE NEWSWIRE) — AppFolio, Inc. (NASDAQ: APPF) today announced that it will report its first quarter 2025 financial results after the close of the U.S. financial markets on Thursday, April 24, 2025.

In conjunction with this announcement, AppFolio will host a conference call on Thursday, April 24, 2025, at 5:00 p.m. (Eastern Time), to discuss the company’s financial results and business outlook. A live webcast of the call will be available at https://edge.media-server.com/mmc/p/994jmsnj. To access the call by phone, please go to the following link: https://register-conf.media-server.com/register/BIec9db96ea67145e5b35acbb6ce94b6ad, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on AppFolio’s Investor Relations website at https://ir.appfolioinc.com/news-events/events.

Disclosure Information

AppFolio uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor AppFolio’s Investor Relations website in addition to following AppFolio’s SEC filings, public conference calls, press releases, and webcasts.

About AppFolio

AppFolio is a technology leader powering the future of the real estate industry. Our innovative platform and trusted partnership enable our customers to connect communities, increase operational efficiency, and grow their business. For more information about AppFolio, visit appfolio.com.

Investor Contact:

Lori Barker
[email protected]



Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) to be Presented at the National Kidney Foundation Spring Clinical Meetings

WALTHAM, Mass., April 10, 2025 (GLOBE NEWSWIRE) — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the company will present a post-hoc analysis of the OPTIMIZE Study, an open-label clinical trial of XPHOZAH ® (tenapanor), as a poster at the National Kidney Foundation (NKF) Spring Clinical Meetings, now underway in Boston. Ardelyx is also hosting an Exhibitor Showcase discussing hyperphosphatemia management.

XPHOZAH is the first and only phosphate absorption inhibitor (PAI) approved by the U.S. Food and Drug Administration to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. XPHOZAH offers a different mechanism of action that blocks phosphate absorption at the primary pathway and is administered as a single tablet taken twice daily.

OPTIMIZE was a randomized, open label study which included 330 patients with chronic kidney disease (CKD) on dialysis with hyperphosphatemia. The study was designed to evaluate different methods of optimizing phosphorus management with XPHOZAH in both binder-naïve and binder-treated patients. 

“Now more than one year since the launch of XPHOZAH, we are seeing that patients are receiving the benefits of the treatment and experiencing improved phosphate control,” said David Spiegel, MD, senior vice president, nephrology at Ardelyx. “At the same time, we recognize how important it is to continue to understand the patient experience and provide insights in how to help patients have a positive experience with the therapy to support adherence to treatment and achieve target phosphate goals. Analyses, like the one presented at NKF Spring Clinical Meetings, provide insight into methods that healthcare providers can use to optimize treatment with XPHOZAH. In this case, it was observed that among patients experiencing loose stools on XPHOZAH, those who used an anti-diarrheal medication had a lower rate of treatment discontinuation due to diarrhea.”

Poster #G-310, entitled

“Tenapanor-Treated Patients Using Over-the-Counter Antidiarrheal Agents Saw Decreased Stool Frequency and Improved Stool Consistency,”
is a post hoc analysis of the OPTIMIZE study and evaluated discontinuation rates and changes in stool frequency and consistency in patients receiving tenapanor who self-medicated with the over-the-counter antidiarrheal agent loperamide. The analysis found that among the 40% of patients with reported diarrhea, 9.7% of patients that were also using loperamide discontinued tenapanor due to diarrhea compared to 24.6% of patients not using loperamide. In conclusion, loperamide was identified as a treatment option to improve diarrhea emergent with tenapanor treatment.

Poster presentations are now publicly available and can be accessed on demand here.

In addition to the poster presentation during NKF Spring Clinical Meetings, Ardelyx is sponsoring an Exhibitor Showcase titled: “A Different Perspective on Hyperphosphatemia Management: Evaluating Current Strategies” on April 11, 2025, from 12:00-12:35 PM EDT, where Dr. Vincent Carsillo, will discuss first-in-class PAI, XPHOZAH. The presentation will review the XPHOZAH mechanism of action, efficacy and safety data from the Phase 3 clinical trial program and will include a discussion about the clinical application of XPHOZAH as add-on therapy for the many dialysis patients on a phosphate binder with serum phosphorus levels above guideline-established targets.

About XPHOZAH® (tenapanor)

XPHOZAH, discovered and developed by Ardelyx, is a first-in-class, phosphate absorption inhibitor with a differentiated mechanism of action that acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), thereby reducing phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption. XPHOZAH is a single tablet, taken twice daily. Diarrhea was the most common side effect experienced by patients taking XPHOZAH in clinical trials. Please see additional full Prescribing Information.

About Hyperphosphatemia

Hyperphosphatemia is a serious condition, defined as elevated levels of phosphate in the blood, which affects the vast majority of the 550,000 patients in the United States with chronic kidney disease (CKD) on maintenance dialysis. The kidneys are responsible for eliminating excess phosphate and as kidney function declines, phosphate is not adequately eliminated from the body. As a result, hyperphosphatemia is a nearly universal condition among people with CKD on maintenance dialysis, with internationally recognized KDIGO treatment guidelines that recommend lowering elevated phosphate levels toward the normal range (2.5-4.5mg/dL).

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

XPHOZAH is contraindicated in:

  • Pediatric patients under 6 years of age
  • Patients with known or suspected mechanical gastrointestinal obstruction

WARNINGS AND PRECAUTIONS

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

MOST COMMON ADVERSE REACTIONS

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in the XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

INDICATION

XPHOZAH (tenapanor), 30 mg BID, is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

For additional safety information, please see full Prescribing Information.

About Ardelyx

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.

Investor and Media Contacts:

Lindsey Manuel
[email protected]